Jérémie Waicenberg

Mablink Bioscience is a French biotechnology company that is actively involved in the fight against cancer by bringing disruptive therapeutic solutions. With its Antibody-Drug Conjugates (ADC) masking technology, Mablink Bioscience aims to dramatically improve the efficiency of ADC therapies and accelerate the development of new treatments. Based in Lyon, where it is developing an unprecedented innovation center, Mablink currently has around 30 employees with diverse backgrounds.

Spécialiste du développement des entreprises françaises non cotées, UI s’engage et s’investit, depuis plus de 50 ans, aux côtés de dirigeants de startups, PME et d’ETI en croissance pour faire émerger et développer des entreprises économiquement et durablement performantes. UI Investissement gère de lordre d’1,5 milliard d’euros d’actifs et s’investit auprès de 300 dirigeants dans des secteurs d’activité essentiels à la société comme la santé, l’agro-business ou l’industrie et les services. Le capital développement et transmission, cœur historique de l’activité d’UI représente plus de la moitié de l’actif sous gestion et permet de faire bénéficier plus de 50 entreprises de l’expertise opérationnelle et des outils méthodologiques développés par UI. En parallèle, les équipes et véhicules d’investissement dédiés à l’innovation et à la consolidation permettent d’accompagner les entreprises tout au long de leur cycle de vie et de contribuer au dynamisme économique des territoires. UI s’appuie aujourd’hui sur près de 80 collaborateurs et, en complément de ses équipes de Paris, sur plus de 10 implantations régionales (Besançon, Clermont-Ferrand, Dijon, Lille, Limoges, Lyon, Nantes, Orléans, Reims, Rennes, Strasbourg…).

Mablink Bioscience is a French biotechnology company that is actively involved in the fight against cancer by bringing disruptive therapeutic solutions. With its Antibody-Drug Conjugates (ADC) masking technology, Mablink Bioscience aims to dramatically improve the efficiency of ADC therapies and accelerate the development of new treatments. Based in Lyon, where it is developing an unprecedented innovation center, Mablink currently has around 30 employees with diverse backgrounds.

Abterra is a tribute to the land (terra in latin). The respect for the land shapes each of our creations. Respect expressed by the time taken to observe it, to listen to it and to touch it, to understand it and to preserve it; to let it express all its richness to produce an exceptional extra virgin olive oil.

Merieux Equity Partners is a multistage investment manager specialized in the healthcare & nutrition sectors via two dedicated platforms: Venture and Growth/Buyout. As an independent General Partner - registered under the French Financial Markets Authority AMF ("Autorité des Marchés Financiers") - Merieux Equity Partners currently manages 5 main funds, representing more than €1 billion of Commitments, and has supported over 45 companies in Europe and North America since its creation - in Venture Capital and Growth/Buyout. Our passion is to work alongside entrepreneurs and companies with an ambitious growth plan, offering them privileged access to our sector-expertise and cross-border experience. With a team of 24 full-time employees and 6 Senior Advisors, we strive to bring the best of our operational experience and privileged access to Merieux industrial network.

Seventure Partners is a long term equity investor that actively supports innovative companies aiming at generating positive impacts on Humankind, Society, Sustainability and the Planet. With €950m net commitments under management as of the end of 2022, Seventure is a leading venture capital firm in Europe investing since 1997 in innovative businesses with high growth potential in 2 main areas: Life sciences (Biotech, Health & digital Health, Nutrition, Foodtech, Blue Economy, Aquaculture, Animal & Agriculture, Sport & Wellness …) with a specific interest for microbiome-related innovations across Europe, Israel, Asia and North America and Digital technologies (FinTech, RetailTech etc…) in Western Europe. Investments can range between €500k and €10m per round and up to €20m per company, from early to late stage, growth, pre-IPO and IPO. Investments can range between €500k and €10m per round, or up to €20m per company, from early to late stage. Seventure is a subsidiary of Natixis Global Asset Management. Natixis is the corporate investment management and financial services arm of Groupe BPCE, the second-largest French bank. For more details: www.seventure.com